Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

1,163 questions · 1,209 findings · 133 reviews · Headline outcomes only

No studies found 176 · 14.6%GRADE not reported 47 · 3.9%Very low 241 · 19.9%Low 323 · 26.7%Moderate 315 · 26.1%High 107 · 8.9%

Intermittent 'as needed' ICS vs daily ICS

Patients with serious adverse health events (duration 12 to 52 weeks) · Children and adults with persistent asthma.

Intermittent 'as needed' ICS showed no clear difference in patients with serious adverse health events (duration 12 to 52 weeks) compared with daily ICS (low certainty).

1 finding from 1 review

Intermittent 'as needed' ICS vs daily ICS

Patients with at least 1 exacerbation requiring emergency department/acute care visit (duration 12 to 52 weeks) · Children and adults with persistent asthma.

Intermittent 'as needed' ICS showed no clear difference in patients with at least 1 exacerbation requiring emergency… compared with daily ICS (low certainty).

1 finding from 1 review

Intermittent 'as needed' ICS vs daily ICS

Change from baseline AM PEFR (%) (duration 44 to 52 weeks) · Children and adults with persistent asthma.

Intermittent 'as needed' ICS showed no clear difference in change from baseline AM PEFR (%) (duration 44 to 52 weeks) compared with daily ICS (moderate certainty).

1 finding from 1 review

Intermittent 'as needed' ICS vs daily ICS

Change from baseline mean daily use of β2‐agonists (puffs/day) (duration 24 to 44 weeks) · Children and adults with persistent asthma.

Intermittent 'as needed' ICS showed no clear difference in change from baseline mean daily use of β2‐agonists (puffs/day)… compared with daily ICS (moderate certainty).

1 finding from 1 review